Zhejiang Guobang Pharmaceutical Co., Ltd.

    About us

 

Zhejiang Guobang Pharmaceutical Co., Ltd, founded in October 2000 and located in Shangyu District in the city of Shaoxing , Zhejiang province, is the core enterprise affiliated to Guobang Pharmachem Group. It is situated in the very center of the line connecting Hangzhou and Ningbo, which is the hinterland of Yangtse River Delta economic circle.There are two over-sea bridges leading towards Shanghai, so the company boasts a very convenient transportation with airport, railway, expressway, national highway, canal and port.

 

As an intensive new high-tech enterprise of National Torch Plan, the company has been approved by national second-level safety standardization, quality management system of ISO9001: 2008 and environmental management system of ISO14001. All the products have been approved by national medicine and veterinary. Some leading products have acquired certificates of EUGMP, FDA, PMDA, ANVISA and KFDA. The company owns a Nationally Post-Doctoral Research Centre, a Provincial Institute of medicine and an Enterprise Technical Centre.

 

With an area of 500 mu a total assets of 1.81 billion, the company achieved an output value of more than 1.8 billion in 2017. 32 percent of its staff of over 1300 holds a junior college degree from Tsinghua University, Zhejiang University, Tianjin University, Huazhong University of Science and Technology, Dalian University of Technology and China Pharmaceutical University, playing significant roles in positions of scientific research, production, management and sales.

 

As a famous producer of domestic chemical synthetic pharmaceutical APIs and veterinary drugs, the company is mainly engaged in research, production and management of these drugs, centering on pharmaceutical and chemical technologies. Leading products of the company are Quinolone antibacterial drugs, macrolides antibacterial drugs, cephalosporin antibacterial drugs, of which Ciprofloxacin Hydrochloride, Enrofloxacin, Azithromycin, Clarithromycin, Roxithromycin,Ceftezole Sodium and Mabofloxacin are global. Both the production capacity and market share are over 35 percent of domestic and international market. The markets of the company covers 103 countries and regions and its sales network reaches throughout the country and U.S. and European markets.

 

On the basis of adhering to striving for the best, the social idea of “Founding of people and the country, prospering of enterprise and nation”, the professional aim of “Share the beauty of science, nature and life”, and acting program of “Innovation and creation, increasing and upgrading, establishment of personnel and team”. The company will commit to developing the pharmaceutical industry, undertaking the social responsibility of pharmaceutical enterprises, contributing to the society with excellent products, and striving to make new contributions to the health of the people.

 

168彩票